Free Trial
NASDAQ:RCKT

Rocket Pharmaceuticals Q1 2025 Earnings Report

Rocket Pharmaceuticals logo
$3.00 +0.05 (+1.52%)
As of 12:08 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rocket Pharmaceuticals EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.58
Beat/Miss
Beat by +$0.02
One Year Ago EPS
-$0.66

Rocket Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rocket Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Rocket Pharmaceuticals' Q2 2025 earnings is scheduled for Monday, August 4, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Rocket Pharmaceuticals Earnings Headlines

What is Chardan Capital's Forecast for RCKT FY2025 Earnings?
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.
Leerink Partnrs Has Positive Forecast for RCKT Q2 Earnings
What is Lifesci Capital's Forecast for RCKT Q2 Earnings?
See More Rocket Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rocket Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rocket Pharmaceuticals and other key companies, straight to your email.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals (NASDAQ:RCKT), together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

View Rocket Pharmaceuticals Profile

More Earnings Resources from MarketBeat